WHO approves world’s 2nd malaria vaccine; cheaper & easier to produce
New Delhi: The World Health Organization (WHO) has given its endorsement to a cost-effective and highly efficient malaria vaccine developed through collaboration between the Pune-based Serum Institute of India (SII) and the University of Oxford in the…
Covishield, Covaxin price cuts to Rs 225 per dose for private hospitals
JNS: The prices of Covid vaccine, COVISHIELD (Serum Institute) and COVAXIN (Bharat Biotech) have been slashed for private hospitals. The price of the Covishield vaccine has been reduced from 600 rupees to 225 rupees per dose for private hospitals,…
India approves 2 more Vaccines, 1 Pill to fight against COVID
by Ashis Sinha Two more vaccinations and one antiviral medicine have received emergency use authorization from the Government of India to help fight the continuing Covid-19 outbreak, informed health minister Mansukh Mandaviya. “CDSCO, health ministry has…
COVID-19 Vaccine for children aged 3+ to be launched in next 6 months : Poonawalla
JNS I New Delhi: Covid-19 deterrent vaccine for children of age more than three years will be available in the country within next six months. Adar Poonawalla, CEO Serum Institute of India (SII) on Tuesday said, we are planning to launch a vaccine for…
COVID jab for kids by first quarter of 2022: Poonawalla
JNS: Covovax, another COVID-19 vaccine, being manufactured by Serum Institute of India, will be launched in October for adults and for children by the first quarter of 2022, said Adar Poonawalla, CEO of Serum Institute of India (SII) on Friday…
Covishield 2nd dose interval increases to 12-16 weeks
Ashis Sinha I JNS: The government has increased the intervals between two doses of Covishield to 12 to 16 weeks from the existing 6 to 8 weeks on Thursday. This is the second time in three months when the government has increased the gap between the two…
Covaxin gets approval for phase 2, 3 trials on 2-18 year-olds
JNS: An expert panel on Tuesday recommended Covaxin (COVID-19 vaccine) for phase-2 and phase-3 clinical trial on younger population aged between 2 to 18 years, official sources said. The trial will take place in 525 subjects at various sites, including…
Covishield shortage ends after July: Poonawalla
# The government of India had paid an advance of over Rs 2,500 crore to Serum Institute of India (for Covishield) and Bharat Biotech (Covaxin) for supply of 16 crore doses of Covid vaccines between May and July. Ashis Sinha I New Delhi: Adar Poonawalla,…
Adar Poonawalla will back to India soon
JNS: Adar Poonawalla, CEO of the Serum Institute of India (SII), the largest producer of vaccines globally, said in a tweet that “he will return to India from London in a few days.” He left for London along with his family alleging…
SII reduces price of Covishield from Rs 400 to Rs 300 for states
JNS: Serum Institute of India (SII) has slashed the price of Covishield vaccine by Rs 100 for the state government. While, for the private hospitals it remains at Rs 600 per dose. SII, is producing University of Oxford and AstraZeneca’s Covid-19…